Biogen (BIIB) Gross Margin (2009 - 2026)

Biogen has reported Gross Margin for 18 years, with the latest figure at 71.6% in Q2 2026.

• On a quarterly basis, Gross Margin fell 553.0% year-over-year to 71.6% in Q2 2026; TTM through Jun 2026 was 73.99%, a 143.0% decrease from a year earlier, with the FY2025 full-year figure at 75.69%, down 43.0% from the prior year.
• Gross Margin was 71.6% for Q2 2026 at Biogen, down from 73.32% in the prior quarter.
• The five-year high for Gross Margin was 93.55% in Q4 2022, with the low at 70.22% in Q1 2022.
• Average Gross Margin over 5 years is 77.48%, with a median of 76.05% recorded in 2023.
• The largest YoY upside for Gross Margin was 324 bps in 2024 against a maximum downside of 1690 bps in 2024.
• Over 5 years, Gross Margin stood at 93.55% in 2022, then slipped by 0 bps to 93.13% in 2023, then retreated by 18 bps to 76.23% in 2024, then rose by 3 bps to 78.26% in 2025, then decreased by 9 bps to 71.6% in 2026.
• The last three Gross Margin figures came in at 71.6% (Q2 2026), 73.32% (Q1 2026), and 78.26% (Q4 2025), per Business Quant data.